Developer docs
API playgroundTry for free, no card

Search company profiles

Ascendis Pharma

Full company profile

uuid00024cv

Namestring
Ascendis Pharma
Legal namestring
Ascendis Pharma A/S
Company typeenum
Public
Founded yearint
2007
Descriptiontext

Ascendis Pharma A/S is a Denmark-headquartered, Nasdaq-listed (ASND) global biopharmaceutical company founded in 2007 that develops sustained-release prodrug therapeutics using its proprietary TransCon (transient conjugation) platform. The platform links an unmodified parent drug — with established biological activity — to an inert carrier via a cleavable linker, producing predictable, sustained systemic release that can extend dosing intervals from daily to weekly or up to six months while preserving the parent drug's mechanism of action. Three products are FDA-approved: YUVIWEL (navepegritide/TransCon CNP) for achondroplasia in children aged 2+ (approved February 2026 with orphan exclusivity through February 2033), SKYTROFA (lonapegsomatropin/TransCon hGH) for pediatric growth hormone deficiency (approved 2021, expanded to adult GHD July 2025), and YORVIPATH (palopegteriparatide/TransCon PTH) for chronic hypoparathyroidism in adults (approved 2023). The investigational pipeline targets label expansions (adult GHD, Turner syndrome, idiopathic short stature, SHOX deficiency, SGA), a TransCon CNP + TransCon hGH combination, and additional indications in infants and adolescents; the company discontinued its TransCon IL-2 β/γ oncology program in 2026 to concentrate resources on the endocrinology franchise.

The company earns revenue primarily through direct commercialization of its approved rare-disease products, with full-year 2025 product revenue of €720 million (YORVIPATH €477M, SKYTROFA €206M, other €37M), an ~87% gross margin, and €616M in cash; Q1 2026 revenue was €247M, up 154% year-over-year. YUVIWEL is priced at approximately $498,000 per patient per year. The go-to-market combines a dedicated rare-endocrinology field sales force targeting endocrinologists and pediatric specialists across the US and major European countries, supplemented by partner distribution in Japan (Teijin), Greater China (VISEN Pharmaceuticals, a co-controlled JV), and Canada (Pendopharm). Capital is raised via a mix of public equity offerings ($281.3M ADS offering September 2024), capped synthetic royalty funding agreements with Royalty Pharma ($150M each for SKYTROFA in 2023 and YORVIPATH in 2024), and convertible debt (the $575M 2.25% Convertible Senior Notes due 2028 are being redeemed in April 2026). The company employs 1,100+ people across Denmark, Germany, the UK, France, Germany, Italy, Spain, Switzerland, and the US, and its publicly stated Vision 2030 targets at least €5 billion in annual revenue with blockbuster status for each of TransCon PTH, hGH, and CNP.

Short descriptiontext

Ascendis Pharma is a Denmark-headquartered, Nasdaq-listed biopharmaceutical company that uses its proprietary TransCon transient-conjugation platform to develop once-weekly prodrug therapies for rare endocrine diseases, with three FDA-approved products — YUVIWEL (achondroplasia), SKYTROFA (growth hormone deficiency), and YORVIPATH (hypoparathyroidism).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersHellerup, Denmark
HQ citystring
Hellerup
HQ countrystring
Denmark
HQ regionstring
Europe
Markets served

Serves global market

Offices10 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, prodrug technology platform, endocrinology pharmaceuticals, growth hormone therapy, parathyroid hormone replacement
Industry2 codes
PRIMARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Rare Endocrine Disease Therapeutics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Product Sales - YORVIPATH
TypeSubscription Recurring
Description

Sales of YORVIPATH (palopegteriparatide) for chronic hypoparathyroidism in adults. Generated €477 million in full-year 2025 revenue, up significantly from €101 million in the same period last year. Approved in US, EU, EEA, and UK.

finance.yahoo.com
2Product Sales - SKYTROFA
TypeSubscription Recurring
Description

Sales of SKYTROFA (lonapegsomatropin) for growth hormone deficiency. Contributed €206 million in full-year 2025 revenue, with €53 million in Q4. Approved for pediatric GHD and under expansion for adult GHD.

seekingalpha.com
3Product Sales - YUVIWEL
TypeSubscription Recurring
Description

Sales of YUVIWEL (navepegritide) for achondroplasia in children aged 2+. FDA approved February 27, 2026, with commercial launch in early Q2 2026. Priced at approximately $498,000 annually.

in.investing.com
4Royalty Funding
TypeLicensing Royalties
Description

$150 million capped synthetic royalty funding agreement with Royalty Pharma based on U.S. net sales of YORVIPATH. Includes upfront payment with royalty payments ceasing upon reaching a specified multiple.

globenewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Pricing details2 tiers
1YUVIWEL (navepegritide) - approximately $498,000 per year
ModelSubscriptionBilling cadenceAnnual
Notes

YUVIWEL received FDA approval in February 2026 for children aged 2+ with achondroplasia. Wholesale price approximately $498,000 annually, with premium pricing reflecting superior benefits including weekly dosing advantage over daily injection competitors.

in.investing.com
2YORVIPATH and SKYTROFA pricing based on market rates
ModelSubscriptionBilling cadenceAnnual
Notes

Products commercially available in US and EU markets with pricing based on market rates for rare disease therapeutics. YORVIPATH generated €477M revenue in 2025 with strong commercial momentum.

finance.yahoo.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1YUVIWEL
Description

Trade name for navepegritide (TransCon CNP), FDA-approved once-weekly treatment for achondroplasia in children aged 2 and older

ascendispharma.com
+3 more records
Core offering1 text field

Ascendis Pharma is a global biopharmaceutical company that develops and commercializes prodrug-based therapies for rare endocrine diseases using its proprietary TransCon technology platform. The company has three FDA-approved products: YUVIWEL (navepegritide) for achondroplasia, SKYTROFA (lonapegsomatropin) for growth hormone deficiency, and YORVIPATH (palopegteriparatide) for chronic hypoparathyroidism. These therapies are designed to maintain the original mechanism of action of parent drugs while enabling sustained release that reduces dosing frequency.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 86% multi-component response rate in Phase 3 PaTHway Trial at Week 182
+5 more records
Product overview1 text field

Ascendis Pharma is a global biopharmaceutical company that has developed three FDA-approved products using its proprietary TransCon (transient conjugation) technology platform: YUVIWEL (navepegritide) for achondroplasia, SKYTROFA (lonapegsomatropin) for growth hormone deficiency, and YORVIPATH (palopegteriparatide) for hypoparathyroidism. The company operates a platform-plus-products model where TransCon technology enables sustained-release prodrugs designed to improve treatment efficacy, tolerability, and convenience. Their pipeline includes additional indications for these products (TransCon hGH for Turner syndrome and adult GHD, TransCon PTH for dosing expansion, TransCon CNP for broader skeletal disorders) as well as combination therapies and an oncology candidate. The TransCon platform uses three components—an unmodified parent drug, an inert carrier, and a linker—to create prodrugs that maintain original mechanisms of action while enabling weekly or less frequent dosing.

Product and service3 records
1YUVIWEL (navepegritide)
CategoryApproved Rare Disease Therapeutic
Description

FDA-approved once-weekly treatment for children aged 2 years and older with achondroplasia. The first and only weekly therapy for this condition, providing continuous systemic exposure to C-type natriuretic peptide (CNP) to rebalance bone growth.

2SKYTROFA (lonapegsomatropin)
CategoryApproved Rare Disease Therapeutic
Description

FDA-approved once-weekly human growth hormone for pediatric growth hormone deficiency. Approved in the United States, European Union, and EEA. Developed as TransCon hGH, providing sustained release of growth hormone to improve patient adherence.

3YORVIPATH (palopegteriparatide)
CategoryApproved Rare Disease Therapeutic
Description

FDA-approved parathyroid hormone replacement therapy for adults with chronic hypoparathyroidism. Approved in the United States, European Union, EEA, and UK. Designed to restore physiologic levels of PTH 24 hours a day to address both short-term symptoms and long-term complications.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-07-14
Description

Exclusive distribution agreement for YORVIPATH (TransCon PTH) in Canada for treatment of chronic hypoparathyroidism. Pendopharm responsible for regulatory approval and commercialization. YORVIPATH received Health Canada approval in February 2026.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2018-01-01
Description

VISEN Pharmaceuticals was formed in 2018 by Ascendis Pharma with investor syndicate led by Vivo Capital. VISEN has exclusive rights to develop and commercialize Ascendis Pharma's endocrinology rare disease therapies including TransCon hGH, TransCon PTH, and TransCon CNP in Greater China.

3Teijin Pharma
Strategic tierRegionalTypeChannel Partner/ Reseller/ Distributor
Description

Teijin Pharma partnership for development and commercialization of TransCon hGH in Japan (Japan riGHt Trial) and TransCon CNP (Japan ApproaCH Trial) for pediatric GHD and achondroplasia respectively.

ascendispharma.com
Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Established rare disease franchise within AstraZeneca, competing for the same specialty prescriber base. Multiple approved rare disease products with similar commercial model. Jethro Ekuta (Ascendis Chief Regulatory Officer) previously served as VP at Alexion.

TypeBroad incumbent
Description

Markets Genotropin growth hormone franchise and other endocrinology products. Potential competitor in SKYTROFA's market. Large pharma with broader portfolio but overlapping specialty prescriber base and rare disease capabilities.

TypeBroad incumbent
Description

Major player in growth hormone and endocrinology therapeutics (Norditropin franchise). Competes directly with SKYTROFA in GHD market and is a strategic partner ($100M payment). Several Ascendis executives previously worked at Novo Nordisk. Relevant incumbent and potential partner.

TypeBroad incumbent
Description

Profitable rare disease biotech with multiple blockbuster franchises and high gross margins comparable to Ascendis's ~87%. Similar patient-focused commercial model targeting specialty physicians for rare conditions. Represents a relevant benchmark for rare disease commercial maturity.

TypeDirect peer
Description

Specialty biopharma focused on rare diseases including endocrinology and growth disorders. Direct overlap with Ascendis's GHD franchise via partnership and distribution agreements. Comparable rare disease commercial model and European/US presence.

TypeBroad incumbent
Description

Major rare disease player through Genzyme franchise, including endocrinology and rare genetic disorders. Comparable geographic commercial reach and specialty sales infrastructure. Multiple Ascendis executives previously held roles at Genzyme-Sanofi.

TypeDirect peer
Description

Direct competitor in rare endocrine disease therapeutics, particularly in achondroplasia where BioMarin markets Voxzogo. Active in patent litigation with Ascendis over TransCon CNP. Comparable business model focused on rare disease drug development and commercialization.

TypeDirect peer
Description

Rare disease biotech with multiple approved products targeting metabolic and endocrine disorders. Comparable platform-plus-product model focused on underserved rare disease populations. Similar stage of commercial scaling and pipeline expansion.

TypeDirect peer
Description

Global specialty pharma with rare disease and endocrinology focus (including pediatric endocrinology). Overlap with Ascendis's endocrinology rare disease commercial footprint in Europe. Comparable target customer base of endocrinologists and rare disease specialists.

TypeBroad incumbent
Description

Global rare disease and specialty pharma with endocrinology focus. Board member Siham Imani currently heads Global Strategy at Chiesi. Overlapping therapeutic areas including rare endocrine disorders and comparable commercial presence in European markets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries10 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ascendis Pharma

Rare Endocrine Disease Therapeuticsascendispharma.com

Ascendis Pharma is a Denmark-headquartered, Nasdaq-listed biopharmaceutical company that uses its proprietary TransCon transient-conjugation platform to develop once-weekly prodrug therapies for rare endocrine diseases, with three FDA-approved products — YUVIWEL (achondroplasia), SKYTROFA (growth hormone deficiency), and YORVIPATH (hypoparathyroidism).

What Ascendis Pharma does

Ascendis Pharma A/S is a Denmark-headquartered, Nasdaq-listed (ASND) global biopharmaceutical company founded in 2007 that develops sustained-release prodrug therapeutics using its proprietary TransCon (transient conjugation) platform. The platform links an unmodified parent drug — with established biological activity — to an inert carrier via a cleavable linker, producing predictable, sustained systemic release that can extend dosing intervals from daily to weekly or up to six months while preserving the parent drug's mechanism of action. Three products are FDA-approved: YUVIWEL (navepegritide/TransCon CNP) for achondroplasia in children aged 2+ (approved February 2026 with orphan exclusivity through February 2033), SKYTROFA (lonapegsomatropin/TransCon hGH) for pediatric growth hormone deficiency (approved 2021, expanded to adult GHD July 2025), and YORVIPATH (palopegteriparatide/TransCon PTH) for chronic hypoparathyroidism in adults (approved 2023). The investigational pipeline targets label expansions (adult GHD, Turner syndrome, idiopathic short stature, SHOX deficiency, SGA), a TransCon CNP + TransCon hGH combination, and additional indications in infants and adolescents; the company discontinued its TransCon IL-2 β/γ oncology program in 2026 to concentrate resources on the endocrinology franchise.

The company earns revenue primarily through direct commercialization of its approved rare-disease products, with full-year 2025 product revenue of €720 million (YORVIPATH €477M, SKYTROFA €206M, other €37M), an ~87% gross margin, and €616M in cash; Q1 2026 revenue was €247M, up 154% year-over-year. YUVIWEL is priced at approximately $498,000 per patient per year. The go-to-market combines a dedicated rare-endocrinology field sales force targeting endocrinologists and pediatric specialists across the US and major European countries, supplemented by partner distribution in Japan (Teijin), Greater China (VISEN Pharmaceuticals, a co-controlled JV), and Canada (Pendopharm). Capital is raised via a mix of public equity offerings ($281.3M ADS offering September 2024), capped synthetic royalty funding agreements with Royalty Pharma ($150M each for SKYTROFA in 2023 and YORVIPATH in 2024), and convertible debt (the $575M 2.25% Convertible Senior Notes due 2028 are being redeemed in April 2026). The company employs 1,100+ people across Denmark, Germany, the UK, France, Germany, Italy, Spain, Switzerland, and the US, and its publicly stated Vision 2030 targets at least €5 billion in annual revenue with blockbuster status for each of TransCon PTH, hGH, and CNP.

Ascendis Pharma firmographics

Firmographics
Name
Ascendis Pharma
Legal name
Ascendis Pharma A/S
Website
https://ascendispharma.com
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Ascendis Pharma is a Denmark-headquartered, Nasdaq-listed biopharmaceutical company that uses its proprietary TransCon transient-conjugation platform to develop once-weekly prodrug therapies for rare endocrine diseases, with three FDA-approved products — YUVIWEL (achondroplasia), SKYTROFA (growth hormone deficiency), and YORVIPATH (hypoparathyroidism).
Ownership category
akta.pro rank

Ascendis Pharma industry classification

Industry
Product category
Rare Endocrine Disease Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Prodrug technology platform
  • Endocrinology pharmaceuticals
  • Growth hormone therapy
  • Parathyroid hormone replacement

Where Ascendis Pharma is headquartered

Location

Headquarters

HQ city
Hellerup
HQ country
Denmark
HQ region
Europe

Offices10 records

Markets served

Ascendis Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Product Sales - YORVIPATH: Sales of YORVIPATH (palopegteriparatide) for chronic hypoparathyroidism in adults. Generated €477 million in full-year 2025 revenue, up significantly from €101 million in the same period last year. Approved in US, EU, EEA, and UK.
  2. Product Sales - SKYTROFA: Sales of SKYTROFA (lonapegsomatropin) for growth hormone deficiency. Contributed €206 million in full-year 2025 revenue, with €53 million in Q4. Approved for pediatric GHD and under expansion for adult GHD.
  3. Product Sales - YUVIWEL: Sales of YUVIWEL (navepegritide) for achondroplasia in children aged 2+. FDA approved February 27, 2026, with commercial launch in early Q2 2026. Priced at approximately $498,000 annually.
  4. Royalty Funding: $150 million capped synthetic royalty funding agreement with Royalty Pharma based on U.S. net sales of YORVIPATH. Includes upfront payment with royalty payments ceasing upon reaching a specified multiple.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualYUVIWEL (navepegritide) - approximately $498,000 per year
SubscriptionAnnualYORVIPATH and SKYTROFA pricing based on market rates

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Ascendis Pharma product offering

Product offering

Core offering

Ascendis Pharma is a global biopharmaceutical company that develops and commercializes prodrug-based therapies for rare endocrine diseases using its proprietary TransCon technology platform. The company has three FDA-approved products: YUVIWEL (navepegritide) for achondroplasia, SKYTROFA (lonapegsomatropin) for growth hormone deficiency, and YORVIPATH (palopegteriparatide) for chronic hypoparathyroidism. These therapies are designed to maintain the original mechanism of action of parent drugs while enabling sustained release that reduces dosing frequency.

Product overview

Ascendis Pharma is a global biopharmaceutical company that has developed three FDA-approved products using its proprietary TransCon (transient conjugation) technology platform: YUVIWEL (navepegritide) for achondroplasia, SKYTROFA (lonapegsomatropin) for growth hormone deficiency, and YORVIPATH (palopegteriparatide) for hypoparathyroidism. The company operates a platform-plus-products model where TransCon technology enables sustained-release prodrugs designed to improve treatment efficacy, tolerability, and convenience. Their pipeline includes additional indications for these products (TransCon hGH for Turner syndrome and adult GHD, TransCon PTH for dosing expansion, TransCon CNP for broader skeletal disorders) as well as combination therapies and an oncology candidate. The TransCon platform uses three components—an unmodified parent drug, an inert carrier, and a linker—to create prodrugs that maintain original mechanisms of action while enabling weekly or less frequent dosing.

Differentiator

Problem solved

Functional benefit

Brands

  • YUVIWEL: Trade name for navepegritide (TransCon CNP), FDA-approved once-weekly treatment for achondroplasia in children aged 2 and older
  • SKYTROFA
  • YORVIPATH
  • TransCon

Products and services

  • YUVIWEL (navepegritide) FDA-approved once-weekly treatment for children aged 2 years and older with achondroplasia. The first and only weekly therapy for this condition, providing continuous systemic exposure to C-type natriuretic peptide (CNP) to rebalance bone growth.
  • SKYTROFA (lonapegsomatropin) FDA-approved once-weekly human growth hormone for pediatric growth hormone deficiency. Approved in the United States, European Union, and EEA. Developed as TransCon hGH, providing sustained release of growth hormone to improve patient adherence.
  • YORVIPATH (palopegteriparatide) FDA-approved parathyroid hormone replacement therapy for adults with chronic hypoparathyroidism. Approved in the United States, European Union, EEA, and UK. Designed to restore physiologic levels of PTH 24 hours a day to address both short-term symptoms and long-term complications.

Quantifiable outcome

  • 86% multi-component response rate in Phase 3 PaTHway Trial at Week 182
  • +5 more outcomes

Companies that use Ascendis Pharma

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Ascendis Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Ascendis Pharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered regional and core.

  • Pendopharm (Pharmascience Inc.)regionalChannel Partner/ Reseller/ Distributor · 14 July 2024Exclusive distribution agreement for YORVIPATH (TransCon PTH) in Canada for treatment of chronic hypoparathyroidism. Pendopharm responsible for regulatory approval and commercialization. YORVIPATH received Health Canada approval in February 2026.
  • VISEN PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 1 January 2018VISEN Pharmaceuticals was formed in 2018 by Ascendis Pharma with investor syndicate led by Vivo Capital. VISEN has exclusive rights to develop and commercialize Ascendis Pharma's endocrinology rare disease therapies including TransCon hGH, TransCon PTH, and TransCon CNP in Greater China.
  • Teijin PharmaregionalChannel Partner/ Reseller/ DistributorTeijin Pharma partnership for development and commercialization of TransCon hGH in Japan (Japan riGHt Trial) and TransCon CNP (Japan ApproaCH Trial) for pediatric GHD and achondroplasia respectively.

Scale indicators9 records

Recent moves11 records

Expansion highlights6 records

Ascendis Pharma competitors and assessment

Company assessment

Broad incumbents

  • Alexion (AstraZeneca Rare Disease): Established rare disease franchise within AstraZeneca, competing for the same specialty prescriber base. Multiple approved rare disease products with similar commercial model. Jethro Ekuta (Ascendis Chief Regulatory Officer) previously served as VP at Alexion.
  • Pfizer: Markets Genotropin growth hormone franchise and other endocrinology products. Potential competitor in SKYTROFA's market. Large pharma with broader portfolio but overlapping specialty prescriber base and rare disease capabilities.
  • Novo Nordisk: Major player in growth hormone and endocrinology therapeutics (Norditropin franchise). Competes directly with SKYTROFA in GHD market and is a strategic partner ($100M payment). Several Ascendis executives previously worked at Novo Nordisk. Relevant incumbent and potential partner.
  • Vertex Pharmaceuticals: Profitable rare disease biotech with multiple blockbuster franchises and high gross margins comparable to Ascendis's ~87%. Similar patient-focused commercial model targeting specialty physicians for rare conditions. Represents a relevant benchmark for rare disease commercial maturity.
  • Sanofi (Genzyme): Major rare disease player through Genzyme franchise, including endocrinology and rare genetic disorders. Comparable geographic commercial reach and specialty sales infrastructure. Multiple Ascendis executives previously held roles at Genzyme-Sanofi.
  • Chiesi: Global rare disease and specialty pharma with endocrinology focus. Board member Siham Imani currently heads Global Strategy at Chiesi. Overlapping therapeutic areas including rare endocrine disorders and comparable commercial presence in European markets.

Direct peers

  • Swedish Orphan Biovitrum (Sobi): Specialty biopharma focused on rare diseases including endocrinology and growth disorders. Direct overlap with Ascendis's GHD franchise via partnership and distribution agreements. Comparable rare disease commercial model and European/US presence.
  • BioMarin Pharmaceutical: Direct competitor in rare endocrine disease therapeutics, particularly in achondroplasia where BioMarin markets Voxzogo. Active in patent litigation with Ascendis over TransCon CNP. Comparable business model focused on rare disease drug development and commercialization.
  • Ultragenyx Pharmaceutical: Rare disease biotech with multiple approved products targeting metabolic and endocrine disorders. Comparable platform-plus-product model focused on underserved rare disease populations. Similar stage of commercial scaling and pipeline expansion.
  • Ipsen: Global specialty pharma with rare disease and endocrinology focus (including pediatric endocrinology). Overlap with Ascendis's endocrinology rare disease commercial footprint in Europe. Comparable target customer base of endocrinologists and rare disease specialists.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Ascendis Pharma social profiles

Digital presence

Ascendis Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ascendis Pharma leadership team

Management profile

Number of profiles

Profiles17 records

Ascendis Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries10 records

Ascendis Pharma funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ascendis Pharma M&A and investment

M&A and investment

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ascendis Pharma

What does Ascendis Pharma do?

Ascendis Pharma is a global biopharmaceutical company that develops and commercializes prodrug-based therapies for rare endocrine diseases using its proprietary TransCon technology platform. The company has three FDA-approved products: YUVIWEL (navepegritide) for achondroplasia, SKYTROFA (lonapegsomatropin) for growth hormone deficiency, and YORVIPATH (palopegteriparatide) for chronic hypoparathyroidism. These therapies are designed to maintain the original mechanism of action of parent drugs while enabling sustained release that reduces dosing frequency.

Is Ascendis Pharma a public or private company?

Ascendis Pharma is a public company. It is classified as public and is currently operating.

When was Ascendis Pharma founded?

Ascendis Pharma was founded in 2007. It employs 1,001 to 5,000 people.

Where is Ascendis Pharma based?

Ascendis Pharma is headquartered in Hellerup, Denmark, in the Europe region.

How does Ascendis Pharma make money?

Four revenue lines are on record. Product Sales - YORVIPATH is the primary driver. The others are product Sales - SKYTROFA, product Sales - YUVIWEL and royalty Funding.

Who are Ascendis Pharma's main competitors?

Broad incumbents on record are Alexion (AstraZeneca Rare Disease), Pfizer, Novo Nordisk, Vertex Pharmaceuticals, Sanofi (Genzyme) and Chiesi. Direct peers are Swedish Orphan Biovitrum (Sobi), BioMarin Pharmaceutical, Ultragenyx Pharmaceutical and Ipsen.

Does Ascendis Pharma have an API?

No public API is recorded for Ascendis Pharma.

What industry is Ascendis Pharma in?

Ascendis Pharma's product category is Rare Endocrine Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAJ, Rare Endocrine & Growth Disorder Therapies, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldAscendis Pharma A/S $ASND Stock: Aberdeen Group plc Increases HoldingsAberdeen Group plc increased its stake in Ascendis Pharma A/S by 81.4% in Q3, holding 66,250 shares worth $15.09 million. Analysts have a consensus "Moderate Buy" rating with a price target of $312.67, and the stock opened at $271.19.Seeking AlphaAscendis Pharma A/S (ASND) Presents at Jefferies Global Healthcare Conference 2026 TranscriptAscendis Pharma reported Q3 revenue of EUR 366 million, up about 90% year-over-year, with operating expenses of EUR 230 million. The company also highlighted growth across its portfolio and announced new developments.Investing.comAscendis Pharma at Jefferies Global Healthcare Conference: growth plan widensAscendis Pharma outlined its growth strategy at the Jefferies Global Healthcare Conference, citing Q3 2024 revenue of EUR 366 million, up about 90% year over year. Management set long-term revenue targets of EUR 5 billion by 2030 and EUR 10 billion by 2035, driven by its three approved products and label expansions.ChartmillAscendis Pharma (NASDAQ:ASND): Affordable Growth at a Reasonable ValuationAscendis Pharma's commercial launch drove 86% revenue and 112% EPS growth over the past year, with forward estimates of 36% revenue and 43% EPS growth. Its valuation multiples are below industry norms, and its balance sheet shows low leverage, though the trailing P/E remains high.American Banking and Market NewsAscendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $315.00UBS raised its Ascendis Pharma target to $315, keeping a buy rating. The stock opened at $275.39, and the company reported Q3 EPS of $1.03, missing the $1.71 consensus. Analysts expect 3.43 EPS for the current fiscal year.InvestorsAscendis, Among Top 1%, Leads 9 Onto Best Stock ListsAscendis Pharma rose 3% Friday to a 275.39 close, holding a 99 IBD Composite Rating. The biotech reported 373% earnings growth on 67% higher revenue to $463.8 million. It was added to the IBD Big Cap 20 list.TradingViewUBS maintains Ascendis Pharma at Buy, raises price target to $315 from $269UBS maintained Ascendis Pharma at Buy and raised its price target to $315 from $269, a 17.1% increase. The target implies 17.9% upside from the Nov 12 close of $267.07. Other analysts' recent price targets range from $274 to $356.TradingViewWells Fargo maintains Ascendis Pharma at Overweight, raises price target to $330 from $326Wells Fargo maintained Ascendis Pharma at Overweight and raised its price target to $330 from $326. The target implies a 23.6% upside from the Nov 12 close of $267.07. Other analysts' targets range from $274 to $356.TradingViewRBC Capital maintains Ascendis Pharma at Outperform, keeps price target at $290RBC Capital maintained Ascendis Pharma at Outperform with a price target of $290, implying an 8.6% upside from the Nov 12 close of $267.07. Recent analyst price targets range from $274 to $356.